Pre­vail grabs $75M A round in the hunt for new gene ther­a­pies to stop the de­struc­tion caused by Parkin­son's

An­oth­er biotech up­start is com­ing along to com­pete in the fast-grow­ing are­na of gene ther­a­py de­vel­op­ment for neu­rode­gen­er­a­tive dis­eases.

Just a cou­ple of weeks af­ter Ab­b­Vie tied up with Voy­ager on a gene ther­a­py pro­gram for Alzheimer’s, Pre­vail Ther­a­peu­tics is de­but­ing to­day with a $75 mil­lion A round and a mis­sion to go af­ter a dis­ease-mod­i­fy­ing ap­proach to Parkin­son’s dis­ease. The biotech was seed­ed by Or­biMed and the Sil­ver­stein Foun­da­tion.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters